RS91204A - Tečni preparat koji sadrži derivat kamptotecina i farmaceutski preparat koji se može dobiti liofilizacijom ovog preparata - Google Patents

Tečni preparat koji sadrži derivat kamptotecina i farmaceutski preparat koji se može dobiti liofilizacijom ovog preparata

Info

Publication number
RS91204A
RS91204A YU91204A YUP91204A RS91204A RS 91204 A RS91204 A RS 91204A YU 91204 A YU91204 A YU 91204A YU P91204 A YUP91204 A YU P91204A RS 91204 A RS91204 A RS 91204A
Authority
RS
Serbia
Prior art keywords
liquid preparation
glycyl
group
preparation according
alkali metal
Prior art date
Application number
YU91204A
Other languages
English (en)
Serbian (sr)
Inventor
Takahiro Ito
Shinji Narisawa
Original Assignee
Tanabe Seiyaku Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co. Ltd. filed Critical Tanabe Seiyaku Co. Ltd.
Publication of RS91204A publication Critical patent/RS91204A/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
YU91204A 2002-04-16 2003-04-15 Tečni preparat koji sadrži derivat kamptotecina i farmaceutski preparat koji se može dobiti liofilizacijom ovog preparata RS91204A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (1)

Publication Number Publication Date
RS91204A true RS91204A (sr) 2006-12-15

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
YU91204A RS91204A (sr) 2002-04-16 2003-04-15 Tečni preparat koji sadrži derivat kamptotecina i farmaceutski preparat koji se može dobiti liofilizacijom ovog preparata

Country Status (21)

Country Link
US (1) US20050215485A1 (enExample)
EP (1) EP1501549A2 (enExample)
JP (1) JP3927954B2 (enExample)
KR (1) KR100700963B1 (enExample)
CN (1) CN100544769C (enExample)
AR (1) AR039272A1 (enExample)
AU (1) AU2003223120B2 (enExample)
BR (1) BR0309283A (enExample)
CA (1) CA2480425A1 (enExample)
HR (1) HRP20040894A2 (enExample)
ME (1) MEP31308A (enExample)
MX (1) MXPA04010178A (enExample)
MY (1) MY136696A (enExample)
NO (1) NO20044964L (enExample)
PL (1) PL371677A1 (enExample)
RS (1) RS91204A (enExample)
RU (1) RU2315623C2 (enExample)
TW (1) TW200306314A (enExample)
UA (1) UA77295C2 (enExample)
WO (1) WO2003086471A2 (enExample)
ZA (1) ZA200408008B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556254A1 (en) * 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing camptothecins
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
JP6012902B1 (ja) 2014-12-26 2016-10-25 日本化薬株式会社 カンプトテシン類高分子誘導体の医薬製剤
EP3345654A4 (en) * 2015-09-03 2019-05-08 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING A CAMPTOTHECINPOLYMER DERIVATIVE
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
EP4438062A1 (en) * 2021-11-26 2024-10-02 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6815435B2 (en) * 2000-07-13 2004-11-09 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing DDS compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
AU2003223120A2 (en) 2003-10-27
RU2315623C2 (ru) 2008-01-27
CA2480425A1 (en) 2003-10-23
MY136696A (en) 2008-11-28
NO20044964L (no) 2004-11-15
UA77295C2 (en) 2006-11-15
KR100700963B1 (ko) 2007-03-28
TW200306314A (en) 2003-11-16
AU2003223120B2 (en) 2006-10-05
AU2003223120A1 (en) 2003-10-27
WO2003086471A3 (en) 2004-04-15
CN100544769C (zh) 2009-09-30
US20050215485A1 (en) 2005-09-29
MXPA04010178A (es) 2005-06-08
RU2004133349A (ru) 2005-05-27
HRP20040894A2 (en) 2005-10-31
JP2005523329A (ja) 2005-08-04
KR20050000516A (ko) 2005-01-05
CN1646172A (zh) 2005-07-27
BR0309283A (pt) 2005-02-15
AR039272A1 (es) 2005-02-16
MEP31308A (en) 2010-10-10
WO2003086471A2 (en) 2003-10-23
EP1501549A2 (en) 2005-02-02
PL371677A1 (en) 2005-06-27
JP3927954B2 (ja) 2007-06-13
ZA200408008B (en) 2005-06-13

Similar Documents

Publication Publication Date Title
CA2471879C (en) Pharmaceutical composition containing ghrelin
RS91204A (sr) Tečni preparat koji sadrži derivat kamptotecina i farmaceutski preparat koji se može dobiti liofilizacijom ovog preparata
JP2002363097A (ja) 安定化された凍結乾燥型医薬組成物
JP6832281B2 (ja) バンコマイシンの水溶液製剤
EA036982B1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с
KR101024511B1 (ko) 올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
JPH05331071A (ja) カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
CA2809646C (en) 5.alpha.-androstane-3.beta.,5,6.beta.-triol injection and preparation method therefor
US12491229B2 (en) Stabilized peptide composition
KR20220034053A (ko) 재조합 단백질의 안정적인 제형
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
JPH05112464A (ja) 安定化された [Leu13−motilin−Hse 医薬組成物
JPH07173074A (ja) カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US20230364245A1 (en) Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
JPH08231398A (ja) 凍結乾燥製剤
JPH04145022A (ja) 2―0―高級アルキルアスコルビン酸又はその誘導体含有製剤
JP2016079187A (ja) 懸濁液剤